DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Micardis (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Official(s) and/or principal investigator(s):
Boehringer Ingelheim, Study Chair, Affiliation: Boehringer Ingelheim

Summary

Practical experience report (PER) investigating the effect of Micardis« on the average 24h blood pressure of therapy-naive and therapy-experienced patients

Clinical Details

Official title: 24h BP Under Micardis in Daily Practice

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome:

Efficacy (Change of Systolic Blood Pressure)

Efficacy (Change of Diastolic Blood Pressure)

Secondary outcome: Overall Tolerability Scale

Eligibility

Minimum age: 18 Years. Maximum age: 95 Years. Gender(s): Both.

Criteria:

Inclusion criteria: 1. Patients who have recently been diagnosed with hypertension 2. Patients whose current blood pressure treatment are inadequate and needs to be revised are suitable for inclusion. Exclusion criteria: None (according to investigator)

Locations and Contacts

Additional Information

Starting date: April 2009
Last updated: February 28, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017